Incretin-based Therapy in Late Preclinical Type 1 Diabetes

Authors
Category Primary study
Year 2016
The objective of the trial is to study whether daily treatment with liraglutide improves endogenous insulin secretion, postpones progression to overt Type 1 diabetes, and is tolerable and safe in subjects aged 10-30 years, who are positive for multiple islet autoantibodies and have dysglycemia.
Epistemonikos ID: 308538b9eed5f5dbd0f22ba66e29c78e18018673
First added on: Jul 02, 2024